David A. Ruddy

12.9k citations

33 papers · 2.6k indexed · 2 hit papers · h-index 19

Impact in

Hematology top 2%
- Iron Metabolism and Disorders
Genetics top 5%
- Hemoglobinopathies and Related Disorders

Papers in

Transplantation 1
Hematology 4

Co-authors: Daniel P. Rakiec Joshua M. Korn Michael C. Ellis John E. Monahan Frank Stegmeier Annette L. Parks Daniel Curtis William R. Sellers
Journals: Cancer Research (6 papers)Molecular Cancer Therapeutics (4 papers)Molecular Cancer Research (3 papers)Genome Research (2 papers)Cancer Discovery (2 papers)
Partner nations: Switzerland United States China

In The Last Decade

David A. Ruddy

30 papers receiving 2.6k citations

Hit Papers

align trajectories log scale

An F876L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV3100 (Enzalutamide) 2013 · 425 citations

Peers

Countries citing papers authored by David A. Ruddy

Since Specialization

Citations

This map shows the geographic impact of David A. Ruddy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David A. Ruddy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David A. Ruddy more than expected).

Fields of papers citing papers by David A. Ruddy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David A. Ruddy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David A. Ruddy. The network helps show where David A. Ruddy may publish in the future.

Co-authors

The 25 scholars most cited alongside David A. Ruddy, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David A. Ruddy Line = papers co-authored together David A. Ruddy links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Improving the integrity and reproducibility of research that uses antibodies: a technical, data sharing, behavioral and policy challenge mAbs ·Michael Biddle, Panayiota Stylianou, Marek Rękas, Adam Wright, Jaize Viana Ribeiro Sousa, David A. Ruddy, M. Irina Stefana, Katarzyna Kmiecik, Anita Bandrowski, Richard Kahn, Carl Laflamme, Eva M. Krockow, Harvinder Virk	2024	4
2	Abstract 896: Predicting metastatic transcriptomes of patient tumors with deep learning Cancer Research ·Gang Li, Evan Béal, Dean Sumner, Giorgio Giacomo Galli, Viviana Cremasco, Joshua M. Korn, Frank Dondelinger, David A. Ruddy, Audrey Kauffmann, Slavica Dimitrieva	2024	0
3	Phase Ib study testing neoadjuvant transforming growth factor (TGF)-β antibody, NIS793, plus 5-fluorouracil, irinotecan, and oxaliplatin chemotherapy (FOLFIRINOX) in patients (pts) with borderline resectable (BR)/locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC). Journal of Clinical Oncology ·Colin D. Weekes, David T. Ting, Aparna R. Parikh, Stacie Ittershagen, Claire Fabre, Viviana Cremasco, David A. Ruddy, Andrew S. Liss, Aileen O’Shea, Mukesh G. Harisinghani, Michelle Piquet, Jonathan Chang, Eunice L. Kwak, David P. Ryan	2023	1
4	RAF-Mutant Melanomas Differentially Depend on ERK2 Over ERK1 to Support Aberrant MAPK Pathway Activation and Cell Proliferation Molecular Cancer Research ·Matthew S. Crowe, Tatiana Zavorotinskaya, Charles F. Voliva, Matthew D. Shirley, Yanqun Wang, David A. Ruddy, Daniel P. Rakiec, Jeffery A. Engelman, Darrin D. Stuart, Alyson K. Freeman	2021	3
5	Inhibition of MDM2 Promotes Antitumor Responses in p53 Wild-Type Cancer Cells through Their Interaction with the Immune and Stromal Microenvironment Cancer Research ·Hui Qin Wang, Iain J. Mulford, Fiona A. Sharp, Jinsheng Liang, Sema Kurtuluş, Gina M. Trabucco, David S. Quinn, Tyler A. Longmire, Nidhi Patel, Roshani Patil, Matthew D. Shirley, Yan Chen, Hao Wang, David A. Ruddy, Claire Fabre, Juliet Williams, Peter S. Hammerman, Jennifer Mataraza, Barbara Platzer, Ensar Halilovic	2021	43
6	Therapeutic Assessment of Targeting ASNS Combined with l -Asparaginase Treatment in Solid Tumors and Investigation of Resistance Mechanisms ACS Pharmacology & Translational Science ·Verena Apfel, Damien Bégué, Valentina Cordo’, Laura Holzer, Laetitia Martinuzzi, Alexandra Buhles, Gráinne Kerr, Inês Amorim Monteiro Barbosa, Ulrike Naumann, Michelle Piquet, David A. Ruddy, Andreas Weiss, Stéphane Ferretti, Reinaldo Almeida, Débora Bonenfant, Luca Tordella, Giorgio Giacomo Galli	2021	18
7	A CRISPR Screen Reveals Resistance Mechanisms to CD3-Bispecific Antibody Therapy Cancer Immunology Research ·Siqi Liu, Alyssa Grantham, Casey Landry, Brian Granda, Rajiv Chopra, Srinivas Chakravarthy, Sabine Deutsch, Markus Vogel, Katie Russo, Katherine Seiss, William R. Tschantz, Tomáš Rejtar, David A. Ruddy, Tiancen Hu, Kimberly Aardalen, Joel P. Wagner, Glenn Dranoff, Joseph A. D’Alessio	2020	14
8	Distinct Transcriptional Programming Drive Response to MAPK Inhibition in BRAF V600-Mutant Melanoma Patient-Derived Xenografts Molecular Cancer Therapeutics ·Tianshu Feng, Javad Golji, Ailing Li, Xiamei Zhang, David A. Ruddy, Daniel P. Rakiec, Felipe C. Geyer, Jane Gu, Hui Gao, Juliet Williams, Darrin D. Stuart, Matthew J. Meyer	2019	2
9	Hyperactivation of MAPK Signaling Is Deleterious to RAS/RAF-mutant Melanoma Molecular Cancer Research ·Grace P. Leung, Tianshu Feng, Frederic Sigoillot, Felipe C. Geyer, Matthew D. Shirley, David A. Ruddy, Daniel P. Rakiec, Alyson K. Freeman, Jeffrey A. Engelman, Mariela Jaskelioff, Darrin D. Stuart	2018	49
10	Tumor-derived IFN triggers chronic pathway agonism and sensitivity to ADAR loss Nature Medicine ·Huayang Liu, Javad Golji, Lauren K. Brodeur, Franklin Chung, Julie Chen, Rosalie deBeaumont, Caroline Bullock, Michael D. Jones, Gráinne Kerr, Li Li, Daniel P. Rakiec, Michael R. Schlabach, Sosathya Sovath, Joseph D. Growney, Raymond Pagliarini, David A. Ruddy, Kenzie D. MacIsaac, Joshua M. Korn, E. Robert McDonald	2018	221
11	A Chemical Genetics Approach for the Functional Assessment of Novel Cancer Genes Cancer Research ·Qianhe Zhou, Adnan Derti, David A. Ruddy, Daniel P. Rakiec, Iris Kao, Michelle Lira, Veronica Gibaja, Homan Chan, Yi Yang, Junxia Min, Michael R. Schlabach, Frank Stegmeier	2015	57
12	FGFR-Mediated Reactivation of MAPK Signaling Attenuates Antitumor Effects of Imatinib in Gastrointestinal Stromal Tumors Cancer Discovery ·Fang Li, Hung Huynh, Xiaoyan Li, David A. Ruddy, Youzhen Wang, Richard Ong, Pierce K. H. Chow, Shumei Qiu, Angela Tam, Daniel P. Rakiec, Robert Schlegel, John E. Monahan, Alan Huang	2015	85
13	Inhibition of Casein Kinase 1 Alpha Prevents Acquired Drug Resistance to Erlotinib in EGFR-Mutant Non–Small Cell Lung Cancer Cancer Research ·Alexandra B. Lantermann, Dongshu Chen, Kaitlin McCutcheon, Greg Hoffman, Elizabeth Frias, David A. Ruddy, Daniel P. Rakiec, Joshua M. Korn, Gregory McAllister, Frank Stegmeier, Matthew J. Meyer, Sreenath V. Sharma	2015	43
14	Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus Molecular Cancer Therapeutics ·Hung Huynh, Huai-Xiang Hao, Stephen L. Chan, David Chen, Richard Ong, Khee Chee Soo, Panisa Pochanard, David T. Yang, David A. Ruddy, Manway Liu, Adnan Derti, Marissa N. Balak, Michael R. Palmer, Yan Wang, Benjamin H. Lee, Dalila Sellami, Andrew X. Zhu, Robert Schlegel, Alan Huang	2015	60
15	Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors Oncogene ·Veronica Gibaja, F Shen, J Harari, Joshua M. Korn, David A. Ruddy, Veronica Saenz-Vash, Huili Zhai, Tomáš Rejtar, C. Paris, Zhengtian Yu, Michelle Lira, David King, Wei Qi, Nicholas Keen, Amr Hassan, Hing Man Chan	2015	107
16	An F876L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV3100 (Enzalutamide) Cancer Discovery ·Manav Korpal, Joshua M. Korn, Xueliang Gao, Daniel P. Rakiec, David A. Ruddy, Shivang Doshi, Jing Yuan, Steve G. Kovats, Sunkyu Kim, Vesselina G. Cooke, John E. Monahan, Frank Stegmeier, Thomas M. Roberts, William R. Sellers, Wenlai Zhou, Ping Zhu Hit paper breakdown →	2013	425
17	A Drug Resistance Screen Using a Selective MET Inhibitor Reveals a Spectrum of Mutations That Partially Overlap with Activating Mutations Found in Cancer Patients Cancer Research ·Ralph Tiedt, Elisa Degenkolbe, Pascal Furet, B.A. Appleton, Sabrina Wagner, Joseph Schoepfer, Emily Buck, David A. Ruddy, John E. Monahan, Michael D. Jones, Jutta Blank, Dorothea Haasen, Peter Drueckes, Markus Wartmann, Clive McCarthy, William R. Sellers, Francesco Hofmann	2011	99
18	Presenilin-Based Genetic Screens in Drosophila melanogaster Identify Novel Notch Pathway Modifiers Genetics ·Matt B. Mahoney, Annette L. Parks, David A. Ruddy, Stanley Tiong, Hanife Esengil, Alexander Phan, Panos Philandrinos, Christopher Winter, Runa Chatterjee, Kari A. Huppert, William W. Fisher, Lynn L'Archeveque, Felipa Mapa, Wendy Woo, Michael C. Ellis, Daniel Curtis	2006	41
19	aph-1 and pen-2 Are Required for Notch Pathway Signaling, γ-Secretase Cleavage of βAPP, and Presenilin Protein Accumulation Developmental Cell ·Ross S. Francis, Garth McGrath, Jianhua Zhang, David A. Ruddy, Mary Sym, Javier Apfeld, Monique Nicoll, Mark Maxwell, Bing Hai, Michael C. Ellis, Annette L. Parks, Wei Xu, Jinhe Li, Mark E. Gurney, Richard L. Myers, Carol S. Himes, Ronald R. Hiebsch, Cara Ruble, Jeffrey S. Nye, Daniel Curtis Hit paper breakdown →	2002	655
20	A 1.1-Mb Transcript Map of the Hereditary Hemochromatosis Locus Genome Research ·David A. Ruddy, Gregory S. Kronmal, Vince Lee, Gabriel A. Mintier, Leah Quintana, Rodolfo Domingo, Nicole C. Meyer, Alivelu Irrinki, Erin E. McClelland, A. Fullan, Felipa Mapa, Theodore B. Moore, Winston Thomas, Deborah B. Loeb, Cyrus L. Harmon, Zenta Tsuchihashi, Roger K. Wolff, Randall C. Schatzman, John N. Feder	1997	71

About David A. Ruddy

David A. Ruddy is a scholar working on Transplantation, Hematology, Oncology, Molecular Biology and Computational Theory and Mathematics, having authored 33 papers that have together received 2.6k indexed citations. Recurring topics across this work include Melanoma and MAPK Pathways (4 papers), CRISPR and Genetic Engineering (4 papers), PI3K/AKT/mTOR signaling in cancer (4 papers), CAR-T cell therapy research (4 papers), Protein Degradation and Inhibitors (3 papers), RNA modifications and cancer (3 papers), Cancer-related gene regulation (3 papers) and Computational Drug Discovery Methods (3 papers). The work is most often cited by research in Hematology (449 citations), Genetics (344 citations), Aging (46 citations), Nutrition and Dietetics (375 citations) and Physiology (517 citations). David A. Ruddy has collaborated with scholars based in Switzerland, United States and China. Frequent co-authors include Daniel P. Rakiec, Joshua M. Korn, Michael C. Ellis, John E. Monahan, Frank Stegmeier, Annette L. Parks, Daniel Curtis, William R. Sellers, Wei Xu and Richard L. Myers. Their work appears in journals such as Cancer Research, Molecular Cancer Therapeutics, Molecular Cancer Research, Genome Research and Cancer Discovery.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact